PMCB Stock Summary and Trading Ideas (Pharmacyte Biotech | NASDAQ:PMCB)

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Pharmacyte Biotech trades on the NASDAQ stock market under the symbol PMCB.

As of December 13, 2024, PMCB stock price climbed to $1.72 with 8,228 million shares trading.

PMCB has a beta of 1.10, meaning it tends to be more sensitive to market movements. PMCB has a correlation of 0.07 to the broad based SPY ETF.

PMCB has a market cap of $13.21 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PMCB traded as high as $3.23 and as low as $1.39.

The top ETF exchange traded funds that PMCB belongs to (by Net Assets): VTI, VXF, DFAC, DFAT.

PMCB has underperformed the market in the last year with a return of -24.7%, while the SPY ETF gained +29.9%. In the last 3 month period, PMCB fell short of the market, returning -9.5%, while SPY returned +7.8%. However, in the most recent 2 weeks PMCB has outperformed the stock market by returning +0.6%, while SPY returned +0.3%.

PMCB support price is $1.55 and resistance is $1.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PMCB shares will trade within this expected range on the day.